Page last updated: 2024-12-11

viprostol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

viprostol: structure given in first source; RN given refers to (5Z,11alpha,13E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438370
CHEMBL ID2107669
SCHEMBL ID564143
MeSH IDM0105646

Synonyms (28)

Synonym
cl-115347
viprostol
viprostol (usan/inn)
D06310
73647-73-1
15-deoxy-16-hydroxy-16-vinyl-pge2 methyl ester
15-(deoxy)-16-hydroxy-16-vinylprostaglandin e2 methyl ester
prosta-5,13-dien-1-oic acid, 16-ethenyl-11,16-dihydroxy-9-oxo-, methyl ester, (5z,11alpha,13e)-
cl 115,347
dhv-pge2me
methyl (z)-7-[(1r,2r,3r)-2-[(e)-4-ethenyl-4-hydroxyoct-1-enyl]-3-hydroxy-5-oxocyclopentyl]hept-5-enoate
(+-)-methyl (z)-7-((1r,2r,3r)-2-((e)-(4rs)-4-butyl-4-hydroxy-1,5-hexadienyl)-3-hydroxy-5-oxocyclopentyl)-5-heptenoate
viprostol [usan:inn:ban]
prosta-5,13-dien-1-oic acid, 16-ethenyl-11,16-dihydroxy-9-oxo-, methyl ester, (5z,11alpha,13e)-(+-)-
viprostolum
unii-o2y6i4y8tf
viprostolum [latin]
o2y6i4y8tf ,
73621-92-8
CHEMBL2107669
viprostol [mart.]
viprostol [usan]
prosta-5,13-dien-1-oic acid, 16-ethenyl-11,16-dihydroxy-9-oxo-, methyl ester, (5z,11a,13e)-(+/-)-
viprostol [inn]
SCHEMBL564143
Q27285247
DTXSID301021620
AKOS040746450

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Following topical dosing with 14C-viprostol in petrolatum and silicone oil, substantial systemic concentrations of radioactivity and decreases in MABP were observed."( Skin metabolism and transdermal absorption of viprostol, a synthetic PGE2 analog, in the rat: effect of vehicle.
Cervoni, P; Chan, PS; Dahlin, DC; Kohlbrenner, M; Nicolau, G; Ronsberg, MA; Saunders, TK; Yacobi, A, 1989
)
0.81
" After oral dosing approx."( Pre-systemic metabolism of viprostol in the monkey following oral and topical administration.
Cosulich, DB; DiCioccio, AT; McWilliams, WE; Nicolau, G; Perkinson, NA; Tonelli, AP; Yacobi, A, 1988
)
0.57
" The optimal dosage proved to be 1000 mcg; the effect may last for 84 hours; higher dosage may be associated with a "steal" phenomenon."( CL115,347, an analogue of prostaglandin E2. Peripheral circulatory effects of single ascending doses administered transdermally in normal subjects and in patients with Raynaud's phenomenon.
Bowcock, SA; Cooke, ED; Kirby, JD; Rustin, MH; Watkins, CJ, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199024 (96.00)18.7374
1990's1 (4.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.46 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (11.11%)5.53%
Reviews1 (3.70%)6.00%
Case Studies1 (3.70%)4.05%
Observational0 (0.00%)0.25%
Other22 (81.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]